Lisen Imprinting Diagnostics

Lisen Imprinting Diagnostics is a cancer diagnostics company developing the QCIGISH Test & Platform, a molecular diagnostic test that detects cancer at its earliest stages using a Loss of Imprinting Biomarker and AI modeling. The company is tackling the problem of indeterminate or ambiguous tumor biopsies, an issue that affects up to 40% of U.S. biopsies each year, leading to unnecessary procedures, delayed treatment, and billions in wasted healthcare spending. Unlike other tests that rely on late-stage genetic or protein signals, LisenID’s approach directly visualizes one of the earliest signs of cancer development, enabling diagnoses with up to 95% accuracy and giving clinicians clarity where existing methods fall short. Relevance to Patients: Biopsies can be stressful, invasive and often inconclusive. By improving accuracy from 60% up to 95%, LisenID’s approach helps patients get clearer answers faster, with fewer repeat biopsies.